1. Home
  2. XERS vs MOFG Comparison

XERS vs MOFG Comparison

Compare XERS & MOFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XERS
  • MOFG
  • Stock Information
  • Founded
  • XERS 2005
  • MOFG 1934
  • Country
  • XERS United States
  • MOFG United States
  • Employees
  • XERS N/A
  • MOFG N/A
  • Industry
  • XERS Biotechnology: Pharmaceutical Preparations
  • MOFG Major Banks
  • Sector
  • XERS Health Care
  • MOFG Finance
  • Exchange
  • XERS Nasdaq
  • MOFG Nasdaq
  • Market Cap
  • XERS 444.0M
  • MOFG 460.9M
  • IPO Year
  • XERS 2018
  • MOFG N/A
  • Fundamental
  • Price
  • XERS $3.09
  • MOFG $33.70
  • Analyst Decision
  • XERS Buy
  • MOFG Hold
  • Analyst Count
  • XERS 3
  • MOFG 2
  • Target Price
  • XERS $4.87
  • MOFG $29.75
  • AVG Volume (30 Days)
  • XERS 1.9M
  • MOFG 91.2K
  • Earning Date
  • XERS 11-08-2024
  • MOFG 10-24-2024
  • Dividend Yield
  • XERS N/A
  • MOFG 2.88%
  • EPS Growth
  • XERS N/A
  • MOFG N/A
  • EPS
  • XERS N/A
  • MOFG N/A
  • Revenue
  • XERS $187,361,000.00
  • MOFG $36,677,000.00
  • Revenue This Year
  • XERS $20.35
  • MOFG N/A
  • Revenue Next Year
  • XERS $16.14
  • MOFG $25.51
  • P/E Ratio
  • XERS N/A
  • MOFG N/A
  • Revenue Growth
  • XERS 22.72
  • MOFG N/A
  • 52 Week Low
  • XERS $1.69
  • MOFG $19.43
  • 52 Week High
  • XERS $3.64
  • MOFG $34.00
  • Technical
  • Relative Strength Index (RSI)
  • XERS 49.74
  • MOFG 68.47
  • Support Level
  • XERS $2.82
  • MOFG $31.50
  • Resistance Level
  • XERS $3.12
  • MOFG $34.00
  • Average True Range (ATR)
  • XERS 0.18
  • MOFG 0.93
  • MACD
  • XERS -0.03
  • MOFG 0.07
  • Stochastic Oscillator
  • XERS 32.93
  • MOFG 94.62

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

About MOFG MidWestOne Financial Gp

MidWestOne Financial Group Inc is a bank holding company engaged in delivering relationship-based business and personal banking products and services. The Bank provides commercial loans, real estate loans, agricultural loans, credit card loans, and consumer loans. It also provides deposit products including demand and interest checking accounts, savings accounts, money market accounts, and time deposits. The Bank also provides products and services including treasury management, Zelle, online and mobile banking, debit cards, ATMs, and safe deposit boxes. The Bank offers its products and services through its network of full-service banking offices. the Bank's investments services department offers financial planning, investment advisory, and retail securities brokerage services.

Share on Social Networks: